摘要
目的：比较两种高危型HPV检测方法在健康体检妇女宫颈癌早期筛查中的应用，选择更适用于宫颈癌早期筛查的检测方法，保护易感人群。方法：应用荧光定量PCR方法和HC2-HPV—DNA两种方法检测健康体检妇女中13种高危型HPV病毒感染情况，并按照年龄分为23～29岁、30～39岁、40～49岁和50～58岁4个年龄组，应用统计学方法对两种检测方法的结果进行分析。结果：在879例健康体检妇女中，荧光定量PCR和HC2-HPV—DNA两种方法检出13种高危型HPV阳性率分别为15．93％（140／879）和11．83％（104／879），两种方法同时检出阳性率为9．56％（84／879），两种方法同时检出阴性率为81．80％（719／879）。两种方法结果均示在40～49岁和50～58岁两个年龄组中，高危型HPV感染率明显升高。统计学分析显示荧光定量PCR和HC2-HPV—DNA两种方法差异有统计学意义（P〈0．05）。结论：HC2-HPV—DNA在13种高危型HPV检测中优于荧光定量PCR方法，更适合大规模健康体检中的应用，可用于大规模人群宫颈癌早期筛查，尤其对于40岁以上妇女进行高危型HPV检测，可有效预防宫颈癌发生。
Objective： This study aims to select the more suitable testing method for early screening of uterine cervical cancer to protect susceptible populations. Application value was compared between the two methods of high-risk HPV detection in early screening of uterine cervical cancer. Methods： The two methods, namely, fluorescence quantitation polymerase chain reaction（PCR） and HC2-HPV-DNA, were used to detect the infection status of 13 high-risk HPV types during women＇s health examination. The examined women were divided into four groups according to age （23 to 29 years old, 30 to 39 years old, 40 to 49 years old, and 50 to 58 years old）. Statistical methods were applied to analyze the results. Results： The detected positive rates by fluorescence quantitation PCR and HC2-HPV-DNA were 15.93% （140/ 879） and 11.83% （104/879）, respectively, among the 879 examined women. The common positive and negative rates were 9.56% （84/879） and 81.80% （719/879）, respectively. The results of the two methods showed that the infection positive rate was obviously higher in the 40 to 49 year old and 50 to 58 year old groups. Statistical difference was observed between fluorescence quantitation PCR and HC2-HPV-DNA in detecting high-risk HPV types （P〈0.05）. Conclusion： HC2-HPV-DNA is superior to fluorescence quantitation PCR for detecting 13 high-risk HPV types and is more suitable for large-scale health screening. HC2-HPV-DNA can be applied in large-scale early screening of uterine cervical cancer, especially in women 〉40 years old who are at high risk of HPV, to prevent uterine cervical cancer efficiently.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2013年第21期1300-1303,共4页
Chinese Journal of Clinical Oncology
